Alligator Bioscience

aka Alligator Bioscience AB, STO:ATORX

Alligator Bioscience is a Swedish biotech that makes antibodies to switch on the immune system inside tumours; its CD40 agonist mitazalimab improved survival with chemotherapy in a pancreatic cancer trial.

Alligator Bioscience, based in Lund, develops tumour-directed immunotherapies from its FIND antibody library and RUBY bispecific format. Mitazalimab (ADC-1013), a CD40 agonist that primes dendritic cells and T cells, was tested with modified FOLFIRINOX in the phase 2 OPTIMIZE-1 trial in first-line metastatic pancreatic cancer, where it produced a higher response rate and longer survival than historical chemotherapy alone, and is being prepared for phase 3. ATOR-4066 is a Neo-X-Prime bispecific against CD40 and CEACAM5.